About this trial
There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18 to 38 years old.
Normal Menstrual cycle of 25-35 days.
Body Weight 60to90 kg
AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,
Disqualifiers
History of premature ovulation
Azoospermia
PCOS
Endometriosis AFS ¾
Trial population
Expected normal responder patients who undergo IVF/ICSI+PGT-A at ART Fertility Clinics Dubai \& Abu Dhabi are willing to participate in the study.
Trial design
Case-only
Prospective
Treatments tested in this trial
Ovarian stimulation with menstruation or after ovulation
Other interventionOvarian stimulation with menstruation or after ovulation
Treatment groups
Trial outcomes
Primary outcomes
Evaluate the Oocyte maturity, Fertilization rate, Blastulation rate, quality Euploidy rate, Premature ovulation rate, Number of injections used and costs
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: